Teva Study Reveals Key HCP Priorities for Tardive Dyskinesia Treatment in Older Patients — Teva Pharmaceutical Industries Ltd.

Event summary

Teva's discrete choice experiment with 489 HCPs identified somnolence risk (26.8%-36.2% decision weight) and short-term symptom improvement (24.4%-29.5%) as top priorities for TD treatment in patients aged ≥55 years.
AUSTEDO® was predicted to be the preferred VMAT2 inhibitor across all patient profiles, driven by its somnolence risk profile, long-term response data, and drug-drug interaction profile.
Interim analysis from the IMPACT-TD Registry showed persistent TD burden in untreated patients, with 89%-96% experiencing at least mild impact and 60%-74% experiencing moderate-to-severe impact over 24 months.
Findings were presented at Psych Congress, held September 15-19, 2026, in New Orleans, LA.

The big picture

Teva's study highlights the critical need for effective TD management, particularly in older patients where treatment decisions are heavily influenced by tolerability and efficacy. The persistent burden of untreated TD underscores the market opportunity for Teva to differentiate AUSTEDO® through targeted clinical and commercial strategies. These insights come at a time when the pharmaceutical industry is increasingly focused on patient-centered care and real-world evidence to drive treatment decisions.

What we're watching

Market Positioning: How Teva will leverage these findings to strengthen AUSTEDO®'s market position against competing VMAT2 inhibitors.
Treatment Adherence: Whether the emphasis on tolerability and efficacy will improve long-term adherence for TD patients.
Regulatory Strategy: The pace at which Teva advances regulatory approvals for AUSTEDO® in new indications or patient populations based on these insights.